Ondine Biomedical (FRA:VF5) Profitability Rank: 0 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:VF5 Ondine Biomedical Inc FRA:VF5
27 GF Score
Price €0.10
GF Value €0.11
! 7 Warning Signs
View Full Analysis

What is Ondine Biomedical Profitability Rank?

Ondine Biomedical has the Profitability Rank of 0.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is rated on a scale of 1 to 10 and is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

A higher score indicates superior profitability, with companies rated 7 or above considered to have more robust and sustainable profit generation. Conversely, a score of 3 or lower suggests challenges in generating consistent profits.

Ondine Biomedical's Operating Margin % for the quarter that ended in Dec. 2025 was -1,068.35%. As of today, Ondine Biomedical's Piotroski F-Score is 2.


Ondine Biomedical Profitability Rank Related Terms


FRA:VF5 vs VRTX, REGN, MRNA: Profitability Rank Comparison

For the Biotechnology subindustry, Ondine Biomedical's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ondine Biomedical Profitability Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ondine Biomedical's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Ondine Biomedical's Profitability Rank falls into.


FRA:VF5
27GF Score
Ondine Biomedical Inc FRA:VF5
Profitability Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ondine Biomedical Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The rank is rated on a scale of 1 to 10. A higher score indicates superior profitability, with companies rated 7 or above considered to have more robust and sustainable profit generation. Conversely, a score of 3 or lower suggests challenges in generating consistent profits.

Ondine Biomedical has the Profitability Rank of 0.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Ondine Biomedical's Operating Margin % for the quarter that ended in Dec. 2025 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2025 ) / Revenue (Q: Dec. 2025 )
=-10.801 / 1.011
=-1,068.35 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

Warning Sign:

Piotroski F-Score of 2 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Ondine Biomedical has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

Warning Sign:

Ondine Biomedical Inc operating margin has been in a 5-year decline. The average rate of decline per year is -3.9%.

4. Consistency of the profitability

5. Predictability Rank

Is Ondine Biomedical (FRA:VF5) Overvalued in 2026?

Based on GuruFocus' analysis, Ondine Biomedical stock appears to be undervalued. The current stock price of €0.10 is trading 11.4% below its estimated GF Value™ of €0.11.

Key valuation signals for FRA:VF5:

  • Profitability Rank: 0
  • GF Value™: €0.11 vs. price of €0.10 (11.4% below fair value)
  • GF Score™: 27/100 with 7 warning signs

No single metric tells the full story. See the FRA:VF5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ondine Biomedical Business Description

Other Exchanges OBIMF:USAOBI:UK
Address 1100 Melville Street, Suite 888, Vancouver, BC, CAN, V6E4A6
Ondine Biomedical Inc is a life sciences company, focusing on the development of photodisinfection-based therapies to provide solutions to drug-resistant infections. The company has created a platform technology called antimicrobial photodynamic disinfection, or photodisinfection, to help prevent and help treat infections across different therapeutic areas in healthcare and industry settings. Canada is the major revenue generator for the group. The company has one reportable operating segment that is antimicrobial photodynamic therapy (aPDT) products.
27GF Score

Get the complete analysis for FRA:VF5

Profitability Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.10
Price
€0.11
GF Value